ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last501 to 520 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
S-268019-b vs Placebo: serious adverse events154 of 9,083

136 of 8,435

0.1 points

-0.3 to 0.5

17,518NCT05212948

A Study of S-268019 for the Prevention of COVID-19

Clostridium Difficile Vaccine vs Placebo: deaths from any cause369 of 8,722

362 of 8,718

0.1 points

-0.5 to 0.7

17,440NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

Clostridium Difficile Vaccine vs Placebo: Number of Participants Reporting Serious Adverse Events (SAEs)719 of 8,722

722 of 8,718

-0.0 points

-0.9 to 0.8

17,440NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

Clostridium Difficile Vaccine vs Placebo: serious adverse events719 of 8,722

722 of 8,718

-0.0 points

-0.9 to 0.8

17,440NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke756 of 8,582

803 of 8,578

-0.6 points

-1.4 to 0.3

17,160NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.417 of 8,582

496 of 8,578

-0.9 points

-1.6 to -0.3

17,160NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapa 10 mg vs Placebo: Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.370 of 8,582

480 of 8,578

-1.3 points

-1.9 to -0.6

17,160NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of All-cause Mortality.529 of 8,582

570 of 8,578

-0.5 points

-1.2 to 0.3

17,160NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapa 10 mg vs Placebo: deaths from any cause529 of 8,582

570 of 8,578

-0.5 points

-1.2 to 0.3

17,160NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapa 10 mg vs Placebo: serious adverse events3,205 of 8,574

3,418 of 8,569

-2.5 points

-4.0 to -1.0

17,143NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Standard Implementation vs Intensive Implementation: deaths from any cause482 of 5,275

855 of 11,758

1.9 points

1.0 to 2.8

17,033NCT02765412

PrOVE QUERI Project #1

Conventional vs suPAR: All Cause Mortality1,126 of 7,901

1,241 of 8,900

0.3 points

-0.7 to 1.4

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: Number of Discharges From the Emergency Room Within 24 Hours3,934 of 7,901

4,352 of 8,900

0.9 points

-0.6 to 2.4

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: Number of Patients With an Admission to the Intensive Care Unit1,027 of 7,901

1,157 of 8,900

-0.0 points

-1.0 to 1.0

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups687 of 7,901

917 of 8,900

-1.6 points

-2.5 to -0.7

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: Number of Admissions to the Medical Ward3,500 of 7,901

3,738 of 8,900

2.3 points

0.8 to 3.8

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: Number of Readmissions687 of 7,901

917 of 8,900

-1.6 points

-2.5 to -0.7

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: deaths from any cause1,126 of 7,901

1,241 of 8,900

0.3 points

-0.7 to 1.4

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Conventional vs suPAR: All Cause Mortality319 of 7,901

359 of 8,900

0.0 points

-0.6 to 0.6

16,801NCT02643459

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Choice for Pediatric Acute Otitis Media7,498 of 9,020

6,828 of 7,778

-4.7 points

-5.7 to -3.6

16,798NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=26

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05212948-sae",
        "title": "S-268019-b vs Placebo: serious adverse events",
        "summary": "154 of 9083 against 136 of 8435; risk difference 0.1 points, 95% interval -0.3 to 0.5; NCT05212948, A Study of S-268019 for the Prevention of COVID-19",
        "record": "/library/comparisons/NCT05212948-sae",
        "nct_id": "NCT05212948",
        "kind": "serious-adverse-events",
        "participants": 17518,
        "risk_difference": {
          "value": 0.0008314548417051697,
          "lower": -0.0029827504738518347,
          "upper": 0.004619229554729929
        },
        "group_1": "154 of 9,083",
        "group_2": "136 of 8,435",
        "difference": "0.1 points",
        "interval": "-0.3 to 0.5",
        "trial_title": "A Study of S-268019 for the Prevention of COVID-19"
      },
      {
        "id": "NCT03090191-deaths",
        "title": "Clostridium Difficile Vaccine vs Placebo: deaths from any cause",
        "summary": "369 of 8722 against 362 of 8718; risk difference 0.1 points, 95% interval -0.5 to 0.7; NCT03090191, Clostridium Difficile Vaccine Efficacy Trial",
        "record": "/library/comparisons/NCT03090191-deaths",
        "nct_id": "NCT03090191",
        "kind": "deaths",
        "participants": 17440,
        "risk_difference": {
          "value": 0.0007835252074491414,
          "lower": -0.005176173487484304,
          "upper": 0.0067450801822503915
        },
        "group_1": "369 of 8,722",
        "group_2": "362 of 8,718",
        "difference": "0.1 points",
        "interval": "-0.5 to 0.7",
        "trial_title": "Clostridium Difficile Vaccine Efficacy Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=27",
  "request_id": "SslZgtMFKTLHQ99s"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?